Precision oncology for acute myeloid leukemia using a knowledge bank approach

Nature Genetics

Volumn 49, Issue 3, 2017, Pages 332-340

  Gerstung, Moritz ^a,b   Papaemmanuil, Elli ^a,c   Martincorena, Inigo ^a   Bullinger, Lars ^d   Gaidzik, Verena I ^d   Paschka, Peter ^d   Heuser, Michael ^e   Thol, Felicitas ^e   Bolli, Niccolo ^a,f   Ganly, Peter ^g   Ganser, Arnold ^e   McDermott, Ultan ^a   Döhner, Konstanze ^d   Schlenk, Richard F ^d   Döhner, Hartmut ^d   Campbell, Peter J ^a,h  

^a WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

^b EUROPEAN BIOINFORMATICS INSTITUTE   (United Kingdom)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d UNIVERSITY OF ULM   (Germany)

^e HANNOVER MEDICAL SCHOOL   (Germany)

^f UNIVERSITY OF MILAN   (Italy)

^g UNIVERSITY OF OTAGO   (New Zealand)

^h UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ACUTE MYELOID LEUKEMIA; ADULT; AGED; ALLOTRANSPLANTATION; ARTICLE; BONE MARROW TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER PROGNOSIS; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL DECISION MAKING; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; EVIDENCE BASED PRACTICE; FEMALE; HUMAN; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LONG TERM SURVIVAL; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; POINT MUTATION; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; STATISTICAL MODEL; ADOLESCENT; CLINICAL TRIAL (TOPIC); DECISION MAKING; GENETICS; MIDDLE AGED; MORTALITY; MULTICENTER STUDY (TOPIC); PERSONALIZED MEDICINE; PROCEDURES; RANDOMIZED CONTROLLED TRIAL (TOPIC); SURVIVAL RATE; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CLINICAL TRIALS AS TOPIC; DECISION MAKING; FEMALE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; PRECISION MEDICINE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SURVIVAL RATE; YOUNG ADULT;

EID: 85009727770     PISSN: 10614036     EISSN: 15461718     Source Type: Journal    
DOI: 10.1038/ng.3756     Document Type: Article

References (34)

1. Van Allen, E.M. et al. Whole-exome sequencing and clinical interpretation of formalin-fixed, paraffin-embedded tumor samples to guide precision cancer medicine. Nat. Med. 20, 682-688 (2014).
2. Mardis, E.R. Genome sequencing and cancer. Curr. Opin. Genet. Dev. 22, 245-250 (2012).
3. Garraway, L.A. & Lander, E.S. Lessons from the cancer genome. Cell 153, 17-37 (2013).
4. McDermott, U., Downing, J.R. & Stratton, M.R. Genomics and the continuum of cancer care. N. Engl. J. Med. 364, 340-350 (2011).
5. Papaemmanuil, E. et al. Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood 122, 3616-3627, quiz 3699 (2013).
6. Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumors. Nature 490, 61-70 (2012).
7. Imielinski, M. et al. Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell 150, 1107-1120 (2012).
8. Manolio, T.A. et al. Global implementation of genomic medicine: we are not alone. Sci. Transl. Med. 7, 290ps13 (2015).
9. Collins, F.S. & Varmus, H. A new initiative on precision medicine. N. Engl. J. Med. 372, 793-795 (2015).
10. Papaemmanuil, E. et al. Genomic classification and prognosis in acute myeloid leukemia. N. Engl. J. Med. 374, 2209-2221 (2016).
11. Cancer Genome Atlas Research Network. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N. Engl. J. Med. 368, 2059-2074 (2013).
12. Gale, R.P., Wiernik, P.H. & Lazarus, H.M. Should persons with acute myeloid leukemia have a transplant in first remission? Leukemia 28, 1949-1952 (2014).
13. Döhner, H. et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 115, 453-474 (2010).
14. Koreth, J. et al. Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials. J. Am. Med. Assoc. 301, 2349-2361 (2009).
15. Flowers, M.E.D. & Martin, P.J. How we treat chronic graft-versus-host disease. Blood 125, 606-615 (2015).
16. Burnett, A.K. et al. Curability of patients with acute myeloid leukemia who did not undergo transplantation in first remission. J. Clin. Oncol. 31, 1293-1301 (2013).
17. Schlenk, R.F. et al. The value of allogeneic and autologous hematopoietic stem cell transplantation in prognostically favorable acute myeloid leukemia with double-mutant CEBPA. Blood 122, 1576-1582 (2013).
18. Doria-Rose, V.P., Harlan, L.C., Stevens, J. & Little, R.F. Treatment of de novo acute myeloid leukemia in the United States: a report from the Patterns of Care program. Leuk. Lymphoma 55, 2549-2555 (2014).
19. Cressman, S. et al. Economic impact of genomic diagnostics for intermediate-risk acute myeloid leukemia. Br. J. Haematol. 174, 526-535 (2016).
20. Khera, N., Zeliadt, S.B. & Lee, S.J. Economics of hematopoietic cell transplantation. Blood 120, 1545-1551 (2012).
21. Forbes, S.A. et al. COSMIC: exploring the world's knowledge of somatic mutations in human cancer. Nucleic Acids Res. 43, D805-D811 (2015).
22. Schoenfeld, D.A. Sample-size formula for the proportional-hazards regression model. Biometrics 39, 499-503 (1983).
23. Schmoor, C., Sauerbrei, W. & Schumacher, M. Sample-size considerations for the evaluation of prognostic factors in survival analysis. Stat. Med. 19, 441-452 (2000).
24. Jameson, J.L. & Longo, D.L. Precision medicine-personalized, problematic and promising. N. Engl. J. Med. 372, 2229-2234 (2015).
25. Stone, R.M. et al. The multi-kinase inhibitor midostaurin (M) prolongs survival compared with placebo (P) in combination with daunorubicin (D)-cytarabine (C) induction (ind), high-dose C consolidation (consol) and as maintenance (maint) therapy in newly diagnosed acute myeloid leukemia (AML) patients (pts) age 18-60 with FLT3 mutations (muts): an international prospective randomized (rand) P-controlled double-blind trial. Blood 126, 6 (2015).
26. Ishwaran, H., Kogalur, U.B., Blackstone, E.H. & Lauer, M.S. Random survival forests. Ann. Appl. Stat. 2, 841-860 (2008).
27. Ley, T.J. et al. DNMT3A mutations in acute myeloid leukemia. N. Engl. J. Med. 363, 2424-2433 (2010).
28. Welch, J.S. et al. The origin and evolution of mutations in acute myeloid leukemia. Cell 150, 264-278 (2012).
29. Delhommeau, F. et al. Mutation in TET2 in myeloid cancers. N. Engl. J. Med. 360, 2289-2301 (2009).
30. Schlenk, R.F. et al; German-Austrian Acute Myeloid Leukemia Study Group. All-trans retinoic acid as adjunct to intensive treatment in younger adult patients with acute myeloid leukemia: results of the randomized AMLSG 07-04 study. Ann. Hematol. 95, 1931-1942 (2016).
31. Schlenk, R.F. et al. Phase 3 study of all-trans retinoic acid in previously untreated patients 61 years or older with acute myeloid leukemia. Leukemia 18, 1798-1803 (2004).
32. Schlenk, R.F. et al. Prospective evaluation of allogeneic hematopoietic stem cell transplantation from matched related and matched unrelated donors in younger adults with high-risk acute myeloid leukemia: German-Austrian trial AMLHD98A. J. Clin. Oncol. 28, 4642-4648 (2010).
33. Therneau, T.M., Grambsch, P.M. & Pankratz, V.S. Penalized survival models and frailty. J. Comput. Graph. Stat. 12, 156-175 (2003).
34. Shah, R.D. & Samworth, R.J. Variable selection with error control: another look at stability selection. J. R. Stat. Soc. Series B Stat. Methodol. 75, 55-80 (2013).